{"id":64009,"date":"2026-04-27T13:45:54","date_gmt":"2026-04-27T05:45:54","guid":{"rendered":"https:\/\/flcube.com\/?p=64009"},"modified":"2026-04-27T13:45:55","modified_gmt":"2026-04-27T05:45:55","slug":"sun-pharma-to-acquire-organon-for-11-75-billion-creating-global-top-25-pharmaceutical-leader-in-branded-generics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64009","title":{"rendered":"Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics"},"content":{"rendered":"\n

Sun Pharmaceutical Industries Ltd<\/strong> (NSE: SUNPHARMA<\/a>) announced a definitive agreement to acquire Organon & Co.<\/strong> (NYSE: OGN<\/a>), a U.S.-based women\u2019s health specialist spun off from Merck & Co. in 2021, in an all-cash transaction valued at USD 11.75 billion<\/strong>.<\/p>\n\n\n\n

The acquisition positions the combined entity as the 25th largest pharmaceutical company worldwide<\/strong> by revenue, with projected annual sales of USD 12.4 billion<\/strong> and a dominant footprint in the established brands and branded generics segment<\/strong>. Notably, 27% of pro forma revenues<\/strong> will derive from innovative medicines, significantly elevating Sun Pharma\u2019s specialty portfolio.<\/p>\n\n\n\n

Deal Structure & Strategic Rationale<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>Sun Pharmaceutical Industries Ltd (India)<\/td><\/tr>
Target<\/strong><\/td>Organon & Co. (USA)<\/td><\/tr>
Transaction Value<\/strong><\/td>USD 11.75 billion (all-cash)<\/td><\/tr>
Enterprise Value \/ LTM Revenue<\/strong><\/td>~9.5x (based on Organon\u2019s $1.24B 2025 revenue)<\/td><\/tr>
Financing<\/strong><\/td>Combination of internal accruals and syndicated debt<\/td><\/tr>
Closing Timeline<\/strong><\/td>Expected Q4 2026, subject to regulatory approvals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Portfolio Synergies & Segment Leadership<\/h2>\n\n\n\n